Objective: To assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different susceptible organ sites. Methods: A systematic review was conducted to identify studies addressing the efficacy of adjuvant HPV vaccination on reducing the risk of recurrence of HPV-related preinvasive diseases. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). Results: Sixteen studies were identified for the final analysis. Overall, 21,472 patients with cervical dysplasia were included: 4132 (19.2%) received the peri-operative HPV vaccine, while 17,340 (80.8%) underwent surgical treatment alone. The recurrences of CIN 1+ (OR 0.45, 95% CI 0.27 to 0.73; p = 0.001), CIN 2+ (OR 0.33, 95% CI 0.20 to 0.52; p < 0.0001), and CIN 3 (OR 0.28, 95% CI 0.13 to 0.59; p = 0.0009) were lower in the vaccinated than in unvaccinated group. Similarly, adjuvant vaccination reduced the risk of developing anal intraepithelial neoplasia (p = 0.005) and recurrent respiratory papillomatosis (p = 0.004). No differences in anogenital warts and vulvar intraepithelial neoplasia recurrence rate were observed comparing vaccinated and unvaccinated individuals. Conclusions: Adjuvant HPV vaccination is associated with a reduced risk of CIN recurrence, although there are limited data regarding its role in other HPV-related diseases. Further research is warranted to shed more light on the role of HPV vaccination as adjuvant therapy after primary treatment.

HPV vaccination after primary treatment of HPV-related disease across different organ sites: a multidisciplinary comprehensive review and meta-analysis / Di Donato, Violante; Caruso, Giuseppe; Bogani, Giorgio; Cavallari, Eugenio Nelson; Palaia, Gaspare; Perniola, Giorgia; Ralli, Massimo; Sorrenti, Sara; Romeo, Umberto; Pernazza, Angelina; Pierangeli, Alessandra; Clementi, Ilaria; Mingoli, Andrea; Cassoni, Andrea; Tanzi, Federica; Cuccu, Ilaria; Recine, Nadia; Mancino, Pasquale; de Vincentiis, Marco; Valentini, Valentino; d’Ettorre, Gabriella; Della Rocca, Carlo; Mastroianni, Claudio Maria; Antonelli, Guido; Polimeni, Antonella; Muzii, Ludovico; Palaia, Innocenza. - In: VACCINES. - ISSN 2076-393X. - 10:2(2022), p. 239. [10.3390/vaccines10020239]

HPV vaccination after primary treatment of HPV-related disease across different organ sites: a multidisciplinary comprehensive review and meta-analysis

Di Donato, Violante;Caruso, Giuseppe;Bogani, Giorgio;Cavallari, Eugenio Nelson;Palaia, Gaspare;Perniola, Giorgia;Ralli, Massimo;Sorrenti, Sara;Romeo, Umberto;Pernazza, Angelina;Pierangeli, Alessandra;Clementi, Ilaria;Mingoli, Andrea;Cassoni, Andrea;Tanzi, Federica;Cuccu, Ilaria;Recine, Nadia;Mancino, Pasquale;de Vincentiis, Marco;Valentini, Valentino;d’Ettorre, Gabriella;Della Rocca, Carlo;Mastroianni, Claudio Maria;Antonelli, Guido;Polimeni, Antonella;Muzii, Ludovico;Palaia, Innocenza
Ultimo
2022

Abstract

Objective: To assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different susceptible organ sites. Methods: A systematic review was conducted to identify studies addressing the efficacy of adjuvant HPV vaccination on reducing the risk of recurrence of HPV-related preinvasive diseases. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). Results: Sixteen studies were identified for the final analysis. Overall, 21,472 patients with cervical dysplasia were included: 4132 (19.2%) received the peri-operative HPV vaccine, while 17,340 (80.8%) underwent surgical treatment alone. The recurrences of CIN 1+ (OR 0.45, 95% CI 0.27 to 0.73; p = 0.001), CIN 2+ (OR 0.33, 95% CI 0.20 to 0.52; p < 0.0001), and CIN 3 (OR 0.28, 95% CI 0.13 to 0.59; p = 0.0009) were lower in the vaccinated than in unvaccinated group. Similarly, adjuvant vaccination reduced the risk of developing anal intraepithelial neoplasia (p = 0.005) and recurrent respiratory papillomatosis (p = 0.004). No differences in anogenital warts and vulvar intraepithelial neoplasia recurrence rate were observed comparing vaccinated and unvaccinated individuals. Conclusions: Adjuvant HPV vaccination is associated with a reduced risk of CIN recurrence, although there are limited data regarding its role in other HPV-related diseases. Further research is warranted to shed more light on the role of HPV vaccination as adjuvant therapy after primary treatment.
2022
HPV; vaccinology; lesion
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
HPV vaccination after primary treatment of HPV-related disease across different organ sites: a multidisciplinary comprehensive review and meta-analysis / Di Donato, Violante; Caruso, Giuseppe; Bogani, Giorgio; Cavallari, Eugenio Nelson; Palaia, Gaspare; Perniola, Giorgia; Ralli, Massimo; Sorrenti, Sara; Romeo, Umberto; Pernazza, Angelina; Pierangeli, Alessandra; Clementi, Ilaria; Mingoli, Andrea; Cassoni, Andrea; Tanzi, Federica; Cuccu, Ilaria; Recine, Nadia; Mancino, Pasquale; de Vincentiis, Marco; Valentini, Valentino; d’Ettorre, Gabriella; Della Rocca, Carlo; Mastroianni, Claudio Maria; Antonelli, Guido; Polimeni, Antonella; Muzii, Ludovico; Palaia, Innocenza. - In: VACCINES. - ISSN 2076-393X. - 10:2(2022), p. 239. [10.3390/vaccines10020239]
File allegati a questo prodotto
File Dimensione Formato  
Romeo_HPV-vaccination_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 5.18 MB
Formato Adobe PDF
5.18 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1613631
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 22
social impact